Ryan Rhodes Purchases 21,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes purchased 21,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $99,750.00. Following the transaction, the chief executive officer owned 626,649 shares of the company’s stock, valued at approximately $2,976,582.75. The trade was a 3.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

FocalTherics Stock Down 2.3%

FOCL opened at $4.26 on Wednesday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The company has a 50 day simple moving average of $5.38. The firm has a market capitalization of $159.66 million, a PE ratio of -4.14 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The business had revenue of $13.20 million for the quarter. As a group, analysts expect that FocalTherics will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on FOCL shares. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research report on Friday. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, FocalTherics currently has an average rating of “Hold” and an average price target of $7.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in FOCL. SmartHarvest Portfolios LLC bought a new stake in shares of FocalTherics in the first quarter valued at approximately $38,000. Lido Advisors LLC bought a new position in FocalTherics during the 1st quarter worth $40,000. Kovack Advisors Inc. acquired a new position in FocalTherics in the 4th quarter valued at $53,000. Leonteq Securities AG bought a new stake in shares of FocalTherics during the 4th quarter valued at $313,000. Finally, Flax Pond Capital LLC bought a new stake in shares of FocalTherics during the 4th quarter valued at $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Key Headlines Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.